Attached To Carbohydrate Compound; Derivative Thereof (e.g., Dna, Nucleotide, Nucleoside, Sugar, Starch, Tannin, Saccharide, Polysaccharide, Cellulose, O-, N- And S-glycoside, Vitamin B12) Patents (Class 424/1.73)
  • Publication number: 20110070158
    Abstract: A sample card and automated quality control module for a radiopharmaceutical synthesis system for conducting quality control tests on approximately one (1) unit dose of a radiopharmaceutical biomarker for use in positron emission tomography. The sample card and quality control module allow operators to conduct quality control tests in reduced time using micro-scale test samples from the radiopharmaceutical solution. The sample card works in conjunction with a microfluidic radiopharmaceutical synthesis system to collect samples of radiopharmaceutical solution on the scale of 5-20 microliters per sample. The sample card then interacts with the quality control module to feed the samples into a number of test vessels, where the samples undergo a number of automated quality control tests.
    Type: Application
    Filed: September 23, 2009
    Publication date: March 24, 2011
    Inventors: Ronald Nutt, Anthony M. Giamis, Aaron McFarland
  • Patent number: 7910086
    Abstract: The invention discloses a pharmaceutical composition of bioactive nanoparticles composed of chitosan, poly-glutamic acid, and a bioactive agent for oral delivery. The chitosan-based nanoparticles are characterized with a positive surface charge and enhanced permeability for oral drug delivery.
    Type: Grant
    Filed: April 21, 2010
    Date of Patent: March 22, 2011
    Assignees: GP Medical, Inc., National Tsing Hua University
    Inventors: Hsing-Wen Sung, Hosheng Tu
  • Patent number: 7910594
    Abstract: This invention relates to vitamin-mitomycin conjugates, to a method of using the conjugates to selectively eliminate a population of pathogenic cells in a host animal harboring the pathogenic cells, and to a method of preparation of the conjugates. The conjugate is of the general formula B-L-X wherein the group B is a vitamin, or an analog or a derivative thereof, that binds to a surface accessible vitamin receptor that is uniquely expressed, overexpressed, or preferentially expressed by a population of pathogenic cells, wherein the group L comprises a cleavable linker, and wherein the group X comprises a mitomycin compound, or an analog or a derivative thereof. An additional therapeutic agent, such as a chemotherapeutic agent, can be administered in combination with the conjugate.
    Type: Grant
    Filed: May 13, 2003
    Date of Patent: March 22, 2011
    Assignee: Endocyte, Inc.
    Inventors: Iontcho Radoslavov Vlahov, Christopher P. Leamon
  • Publication number: 20110064659
    Abstract: Differential expression of nucleic acids in the brains of subjects suffering from late-onset depression has been demonstrated. The invention provides methods useful in the determination of late-onset depression. Also provided by the present invention is a screening method for the identification of compounds for treatment, prevention or diagnosis of late-onset depression.
    Type: Application
    Filed: May 15, 2009
    Publication date: March 17, 2011
    Inventors: Peter Hanson, Duncan Hiscock, Chris Morris, Alan Thomas
  • Patent number: 7906103
    Abstract: Disclosed are Drug Delivery Molecules (DDMs) which both facilitate functional imaging, as by PET, MRI or SPECT, and create a biological effect and methods of their use. These DDMs which are variously designed to target specific receptors, internalized and then function biologically, as for purposes of cell destruction or therapy.
    Type: Grant
    Filed: October 16, 2006
    Date of Patent: March 15, 2011
    Inventor: Gerhard Graupner
  • Publication number: 20110059014
    Abstract: Embodiments of the present disclosure provide for compounds and methods of making compounds such as those shown in FIGS. 1.1A and 1.1B having formula 2, 3, 4, 5, 11, and 12 and formula 2?, 4?, and 11?, as well as uses for the compounds for imaging, and the like.
    Type: Application
    Filed: September 3, 2010
    Publication date: March 10, 2011
    Inventors: Mohammad Namavari, Sanjiv Sam Gambhir, Beverly S. Mitchell
  • Patent number: 7901666
    Abstract: The invention discloses a pharmaceutical composition for treating a subject comprising two or more bioactive nanoparticles, thus treating the subject by co-administering the bioactive nanoparticles to the subject, wherein a first and a second bioactive nanoparticles comprise a shell portion that is dominated by positively charged chitosan, a core portion that contains negatively charged substrate, and at least a first bioactive agent in the first nanoparticle and a second bioactive agent in the second nanoparticle.
    Type: Grant
    Filed: June 1, 2009
    Date of Patent: March 8, 2011
    Assignees: GP Medical, Inc., National Tsing Hua University
    Inventors: Hsing-Wen Sung, Hosheng Tu
  • Patent number: 7888330
    Abstract: The present invention provides phosphoramidate derivatives of a furanosyluracil analog, FAU, that can effectively deliver FAU monophosphate, or a derivative thereof, intracellularly. FAU-Phosphoramidate diesters can bypass the first step of phosphorylation and be activated intracellularly so as to be converted to nucleoside monophosphates. This results in improved formation of nucleoside triphosphates, and higher incorporation into DNA. The compounds of the invention can be used to treat cancer.
    Type: Grant
    Filed: November 9, 2006
    Date of Patent: February 15, 2011
    Assignee: Wayne State University
    Inventors: Anthony F. Shields, Jiri Zemlicka, Sridhar Nimmagadda
  • Patent number: 7883687
    Abstract: This invention relates to novel 15O-labeled monosaccharide useful for positron emission tomography (PET) and producing method thereof.
    Type: Grant
    Filed: March 28, 2005
    Date of Patent: February 8, 2011
    Assignees: Astellas Pharma Inc.
    Inventors: Eiichi Nakamura, Shintaro Nishimura, Yoshihiro Murakami, Hideki Yorimitsu
  • Publication number: 20110027174
    Abstract: The present invention provides a novel approach to cancer therapy and diagnostics that utilizes nanotubes and other similar nanostructures as both an indirect source of radiation therapy (BNCT), and as delivery vehicles for other types of radio- and chemo-therapeutic materials, as well as imaging agents for diagnostic purposes.
    Type: Application
    Filed: October 15, 2010
    Publication date: February 3, 2011
    Inventors: Dan A. Buzatu, Jon G. Wilkes, Dwight Miller, Jerry A. Darsey, Tom Heinze, Alex Birls, Richard Beger
  • Patent number: 7879313
    Abstract: The invention discloses nanoparticles composed of chitosan, poly-glutamic acid, and at least one bioactive agent characterized with a positive surface charge. The bioactive agent is hydrophobic or lipophilic in nature and is associated with micelles before being encapsulated in nanoparticles.
    Type: Grant
    Filed: May 24, 2010
    Date of Patent: February 1, 2011
    Assignees: GP Medical, Inc., National Tsing Hua University
    Inventors: Hsing-Wen Sung, Hosheng Tu
  • Patent number: 7879312
    Abstract: The invention discloses the nanoparticles composed of chitosan, poly-glutamic acid, and at least one DNA/RNA or bioactive agent characterized with a positive surface charge and their enhanced permeability for gene delivery and bioactive agent delivery.
    Type: Grant
    Filed: May 23, 2009
    Date of Patent: February 1, 2011
    Assignees: GP Medical, Inc., National Tsing Hua University
    Inventors: Hsing-Wen Sung, Shu-Fen Peng, Hosheng Tu
  • Patent number: 7875291
    Abstract: A nutritional supplement includes a first formulation including minerals: chromium polynicotinate, magnesium glycinate, manganese sulfate, selenium, vanadyl sulfate, zinc gluconate, copper gluconate, iodine, and boron; and vitamins: vitamins C, B1, B2, B3, B6, B12, and D, biotin, alpha-lipoic acid, and folic acid. The second formulation, packaged separately from the first, includes essential fatty acids: evening primrose oil, flax seed oil, sunflower oil, sesame seed oil, and pumpkin seed oil; and vitamins: vitamin E and vitamin Q-10. A method for improving metabolic function includes consuming the first and second formulation. A method of formulating a composition for improving metabolic function includes packaging together the first formulation and packaging together and separately from the first formulation the second formulation.
    Type: Grant
    Filed: January 17, 2008
    Date of Patent: January 25, 2011
    Assignee: Glu-Pro, Inc.
    Inventors: Amid Habib, Samuel E. Crockett, Claude T. Isler, Sam Pratt
  • Publication number: 20110002849
    Abstract: The present invention relates to a method to assist in the determination of therapy for a patient suffering from Barrett's oesophagus, especially where first-line therapy has been unsuccessful and when dysplasia has been diagnosed. The method comprises the use of an imaging agent comprising a vector which targets (a) Her2, (b) cMet, (c) guanylyl cyclase or (d) IGF1R. The imaging agent is suitable for radioisotope or optical imaging in vitro or preferably in vivo.
    Type: Application
    Filed: February 26, 2009
    Publication date: January 6, 2011
    Inventors: Antonios Danikas, Clifford Smith, Ian A. Wilson
  • Patent number: 7862798
    Abstract: The invention relates to compounds and methods for targeting radionuclide-based imaging agents to cells having receptors for a vitamin, or vitamin receptor binding derivative or analog thereof, by using such a vitamin as the targeting ligand for the imaging agent. The invention provides a compound of the formula for use in such methods. In the compound, V is a vitamin that is a substrate for receptor-mediated transmembrane transport in vivo, or a vitamin receptor binding derivative or analog thereof, L is a divalent linker, R is a side chain of an amino acid of the formula H2NCHRCOOH, M is a cation of a radionuclide, n is 1 or 0, K is 1 or 0, and the compound can be in a pharmaceutically acceptable carrier therefor. The vitamin-based compounds can be used to target radionuclides to cells, such as a variety of tumor cell types, for use in diagnostic imaging of the targeted cells.
    Type: Grant
    Filed: October 11, 2006
    Date of Patent: January 4, 2011
    Assignee: Endocyte, Inc.
    Inventors: Christopher P. Leamon, Matthew A. Parker
  • Publication number: 20100322858
    Abstract: We disclose methods of synthesizing radiohalidated organic compounds and their use in positron emission tomography (PET) imaging of cancer cells.
    Type: Application
    Filed: August 22, 2007
    Publication date: December 23, 2010
    Inventors: William Bornmann, Mian Alauddin, Juri Gelovani, Pradip Ghosh, Liwei Guo, Dongmei Han, David Maxwell, Uday Mukhopadhyay, Zhenghong Peng, Aleksandr Shavrin, Yunming Ying
  • Patent number: 7850946
    Abstract: The sensitivity and specificity of the optical modality can be enhanced by the use of highly absorbing compounds as contrast agents. Novel macrocyclic cyanine and indocyanine bioconjugates that absorb and emit light in the near infrared region of electromagnetic spectrum are disclosed. These compounds are especially useful for endoscopic, localized photoacoustic, and sonofluorescence imaging, detection and therapy of tumors and other abnormalities.
    Type: Grant
    Filed: June 1, 2004
    Date of Patent: December 14, 2010
    Assignee: Washington University in St. Louis
    Inventors: Samuel Achilefu, Yunpeng Ye
  • Publication number: 20100290988
    Abstract: The present invention is directed to fructose-based radiopharmaceuticals, pharmaceutical compositions comprising same, precursors and methods for preparing same, and methods of using same for diagnostic imaging of cancer cells and non-imaging tracer studies.
    Type: Application
    Filed: May 15, 2009
    Publication date: November 18, 2010
    Inventors: Chris CHEESEMAN, Frederick WEST, Tina GRANT, Brendan TRAYNER, John MERCER, Andrei MANOLESCU
  • Publication number: 20100290990
    Abstract: The present invention relates to a method for preparing a 2-fluoropurine marked with the radioisotope 18F comprising a fluorination step for a 2-nitropurine derivative. The present invention comprises a 2-fluoropurine derivative marked with the radioisotope 18F which can be obtained by or during a method according to the invention and its various uses.
    Type: Application
    Filed: December 23, 2008
    Publication date: November 18, 2010
    Inventors: Louisa Barre, Patrice Marchand
  • Publication number: 20100290989
    Abstract: Compositions comprising hyaluronic acid (HA) or agents that interfere with HA binding of HA receptors and methods of using the same are provided. For example, there is provided a composition comprising HA oligomers ranging in size from 10-mer to 80-mer and use of the same for promoting migration, growth or survival of wild-type or transformed/cancerous cells. There is also provided a composition comprising an agent that interferes with binding between an HA oligomer of a size of about 10-mer to about 80-mer and an HA receptor. Such compositions may be useful for therapeutic, diagnostic or imaging applications. Examples of therapeutic use are wound repair or cancer treatment.
    Type: Application
    Filed: October 10, 2008
    Publication date: November 18, 2010
    Applicants: LONDON HEALTH SCIENCES CENTRE RESEARCH INC., REGENTS OF THE UNIVERSITY OF MINNESOTA
    Inventors: Cornelia Tolg, Eva Turley, Jim McCarthy, Leonard G. Luyt
  • Publication number: 20100272645
    Abstract: A myocardial imaging method that is accomplished by administering one or more adenosine A2A adenosine receptor agonist to a human undergoing myocardial imaging.
    Type: Application
    Filed: January 27, 2010
    Publication date: October 28, 2010
    Inventor: Luiz Belardinelli
  • Publication number: 20100254902
    Abstract: The invention relates to stabilised radiopharmaceutical compositions which comprise: (i) an 18F-labelled compound; (ii) an effective stabilizing amount of gentisic acid or a salt thereof with a biocompatible cation; (iii) an aqueous biocompatible carrier medium; wherein the radioactive concentration of the 18F in the carrier medium is in the range 10 to 100,000 MBq/ml and the pH of the composition is in the range 4.0 to 9.5. The invention further comprises methods for preparing such radiopharmaceutical compositions and a new use of gentisic acid or a salt thereof.
    Type: Application
    Filed: November 4, 2008
    Publication date: October 7, 2010
    Inventor: Jan Van Den Bos
  • Publication number: 20100254901
    Abstract: Disclosed herein are aptamers that comprise a nucleic acid sequence that has a specific affinity for a target. These aptamers can be used as delivery vehicles to deliver specific agents to particular sites. Alternatively, targeted aptamers can also be used with detection techniques to determine the presence of absence of specific targets in heterogeneous backgrounds.
    Type: Application
    Filed: July 28, 2006
    Publication date: October 7, 2010
    Inventor: Cassandra L. Smith
  • Publication number: 20100233081
    Abstract: A method is provided for treatment of disorders involving hyperproliferative cells, such as malignancies, advanced stage solid tumors like glioblastoma multiforme, and non-malignant hyperproliferative pathological conditions such as adult macular degeneration. A short range, unselective cell killing radiotherapeutic substance is administered, optionally in a spatially defined volume of tissue, optionally in combination with a mitogenic agent that stimulates or induces DNA biosynthesis. In this way, the percentage of hyperproliferative that are susceptible to killing by the radiotherapeutic agent is increased. Cancer stem cells can be induced to enter S phase with the mitogenic agent, then killed with the radiotherapeutic agent.
    Type: Application
    Filed: May 9, 2008
    Publication date: September 16, 2010
    Applicant: PEAK BIOSCIENCE, INC.
    Inventors: Stephen L. Warren, James E. Matsuura, Michael J. Gerber
  • Patent number: 7790140
    Abstract: In part, the present invention is directed to biocompatible compositions comprising a carrier with a first metal binding domain, a metal ion, an active agent with second metal binding domain and optionally a protective chain covalently attached to the polymeric carrier.
    Type: Grant
    Filed: July 5, 2006
    Date of Patent: September 7, 2010
    Assignee: PharmaIN Corporation
    Inventor: Elijah M. Bolotin
  • Publication number: 20100196273
    Abstract: Compounds for in vivo diagnostic imaging of cellular proliferation are provided. The compounds include L-nucleosides such as a 2?-deoxy-2?-fluoro-L-ara-binofuranosyl pyrimidine nucleoside analogue. These nucleosides are labeled with a positron emitting radioisotope. The present invention also provides a method for in vivo diagnostic imaging of cellular proliferation.
    Type: Application
    Filed: February 11, 2008
    Publication date: August 5, 2010
    Inventors: Mian M. Alauddin, Uday Mukhopadhyay, Juri Gelovani, Ashutosh Pal, William Bornmann
  • Publication number: 20100196272
    Abstract: The subject invention relates to the compositions for radiolabeling Diethylenetriaminepentaacetic Acid (DTPA)-dextran with Technetium-99m and for stabilizing the DTPA-dextran Cold Kit. The composition contains Stannous Chloride ions to reduce 99mTc-pertechnetate, Ascorbic Acid to reduce stannic ions to stannous ions to maintain a reducing environment, ?,?-Trehalose to add bulk and to stabilize the lyophilized composition without interfering with the radiochemical yield, and Glycine to transchelate Technetium-99m under highly acidic conditions to facilitate radiolabeling DTPA-dextran with high radiochemical purity. In addition, the invention pertains to methods for making and using the compositions. The reconstitution of the lyophilized composition by 99mTc-pertechnetate, resulting in radiolabeled 99mTc-DTPA-dextran in a composition between pH 3 to 4.
    Type: Application
    Filed: January 30, 2009
    Publication date: August 5, 2010
    Applicant: NEOPROBE CORPORATION
    Inventors: Gerald Ross Magneson, Richard Cushman Orahood
  • Publication number: 20100183512
    Abstract: Use of protein CTHRC1 or its nucleic acid in preparation for reagents or kits for diagnosing cancer of liver, the method for diagnosing cancer of liver by using the nucleic acid of CTHRC1, kit comprising the antibody to CTHRC1 or nucleic acid probe specific for the CTHRC1 protein and label, and the method for detecting the specific expression of protein CTHRC1 are disclosed.
    Type: Application
    Filed: November 9, 2009
    Publication date: July 22, 2010
    Inventors: Wenxin QIN, Genfu Yao, Xiaozhen Wan, Shengli Yang, Jianren Gu
  • Publication number: 20100178242
    Abstract: The invention provides a method for radiofluorination of biological vectors such as peptides comprising reaction of a compound of formula (II): or a salt thereof with a source of [18F]-fluoride, to give a compound of formula (I): or a salt thereof.
    Type: Application
    Filed: June 18, 2008
    Publication date: July 15, 2010
    Inventors: Alexander Jackson, Rajiv Bhalla
  • Patent number: 7744853
    Abstract: Radiolabeled annexin and modified annexin conjugates useful for imaging vascular thrombi are described. Methods for making and using such radiolabeled annexin conjugates are also provided.
    Type: Grant
    Filed: September 27, 2005
    Date of Patent: June 29, 2010
    Assignee: Poniard Pharmaceuticals, Inc.
    Inventors: Sudhakar Kasina, John M. Reno, Alan R. Fritzberg, Jonathan Tait
  • Publication number: 20100150835
    Abstract: The present invention discloses the reactivity of ponytail (“PT”) sulfonates as leaving groups in nucleophilic fluorination reactions. The results showed that using a pentafluorobenzenesulfonate precursor is a suitable leaving group for n. c. a. nucleophilic 18F-fluorination in synthesis of [18F]fluoromethyl benzene, wherein this is a suitable leaving group for 18F-labeling with moderate reactivity. The PT-precursor seems to be quite stable. In an attempt to purify the crude 18F-labeled product using fluorous solid phase extraction (F-SPE), the radio labeled impurities decreased significantly. This provides an opportunity for utilizing PT methodology in both simple and fast purification methods.
    Type: Application
    Filed: February 26, 2008
    Publication date: June 17, 2010
    Inventors: Bengt Langstrom, Farhad Karimi, Elisabeth Blom
  • Patent number: 7727958
    Abstract: A pharmaceutical formulation for a PKC modulatory peptide and a transport moiety comprising the aforementioned components and an anti-aggregant.
    Type: Grant
    Filed: September 4, 2007
    Date of Patent: June 1, 2010
    Assignee: Kai Pharmaceuticals, Inc.
    Inventor: Mike Tso-ping Li
  • Publication number: 20100119445
    Abstract: The present invention relates to plexin D1 for use as a targetable protein in the treatment or diagnosis of disorders that involve expression of plexin D1. Diagnosis is suitably effected by detecting the presence of plexin D1 in the body or a bodily tissue or fluid, whereas treatment is effected by targeting plexin D1 for delivery of therapeutics to the site where treatment is needed. The invention further relates to the use of molecules that bind plexin D1, a nucleic acid encoding plexine D1 or a ligand of plexin D1 for the preparation of a therapeutical composition for the treatment or diagnosis of disorders that involve expression of plexin D1. The disorders comprise disorders in which plexin D1 is expressed on tumor cells, tumor blood vessels or activated macrophages.
    Type: Application
    Filed: July 20, 2006
    Publication date: May 13, 2010
    Applicant: N.V. Organon
    Inventors: Wilhelmus Petrus Johannes Leenders, Ilse Roodink, Jozef Maria Hendrik Raats
  • Patent number: 7713514
    Abstract: An organized mobile multicomponent conjugate (OMMC) and method of using to enhance binding of weakly binding compounds to a target. A lamellar structure containing at least two binding compounds is assembled under conditions in which the binding compounds self-regulate in or on the lamellar structure, forming a cooperative ensemble that is capable of binding with enhanced affinity to a complementary affinity site on a target. Each binding compound is bound to the lamellar surface, and may be connected by a linker. The OMMC may contain an effector molecule, such as a diagnostic or therapeutic agent, for administration to a patent who is then diagnosed or treated using the effector molecule.
    Type: Grant
    Filed: August 4, 2006
    Date of Patent: May 11, 2010
    Assignee: Mallinckrodt Inc.
    Inventors: Gary L. Cantrell, B. Daniel Burleigh
  • Patent number: 7713528
    Abstract: This invention relates to novel reagent conjugates and a novel multi-step process for delivering active compounds to target analytes of interest in a patient for diagnostic and therapeutic purposes. According to the process, two novel reagents are bound to each other by linkage of the sequence-specific components they contain. The first reagent, which is comprised of a target recognition component and a first sequence-specific component, is introduced into the patient and allowed to achieve maximal localization on the target cells. The second reagent, which is comprised of an active compound component and a second sequence-specific component is then introduced into the patient, thereby forming a complex with the first reagent via the recognition and binding of the sequence-specific components of the two reagents to form the reagent conjugate of the invention. The active compound component is thereby efficiently and specifically delivered to the target analyte.
    Type: Grant
    Filed: June 7, 1995
    Date of Patent: May 11, 2010
    Assignee: Enzo Therapeutics, Inc.
    Inventors: Elazar Rabbani, Jannis G. Stavrianopoulos, Sherry P. Goltz
  • Publication number: 20100111861
    Abstract: A method of measuring the efficacy of an anticancer agent in generating abasic (AP) sites in DNA of cancer cells of a subject includes administering to the subject an anticancer agent that generates AP sites in at least one cancer cell and an AP endonuclease inhibitor probe. The AP endonuclease inhibitor probe includes a detection moiety for detecting the probe in the subject. The amount of probe bound to cancer cells of the subject is then measured. The amount of probe bound to cancer cells of the subject is indicative of efficacy of the anticancer agent in generating AP sites in cancer cells of the subject.
    Type: Application
    Filed: November 2, 2009
    Publication date: May 6, 2010
    Inventors: Lili Liu, Yanming Wang, Stanton Gerson
  • Publication number: 20100111860
    Abstract: A radioactive material containing chitosan for inhibiting cancer and a preparation method thereof are revealed. The adioactive material containing chitosan is formed by using SOCTA chelating agent to connect chitosan and radionuclides such as 188Re, and Tc-99m etc. The preparation method of the radioactive material containing chitosan includes the steps of: prepare SOCTA-Chitosan compound; and prepare M(radionuclide)-SOCTA-Chitosan compound. By biocompatibility and clotting in alkaline environment of human blood of chitosan, the radioactive material containing chitosan is injected into cancer and staying there for a long time so as to achieve effectively treatment.
    Type: Application
    Filed: November 3, 2008
    Publication date: May 6, 2010
    Inventors: Tsai-Yueh LUO, I-Chung Tang, Jian-Wen Chen, Kwei-Luen Hsu, Yu-Lung Wu, Te-Sheng Liang, Chang-Mau Sheng, Jin-Jenn Lin, Ching-Jun Liou, Jyh-Daw Sheu
  • Patent number: 7708978
    Abstract: The present invention relates to an active targeted water-solubility macromolecule polymer, conjugate with interferon and pharmaceutical composition comprising the conjugate. The targeted agent includes, for example, glucose, galatose and the like, as well as their derivates. The conjugate of the present invention is well in water-solubility and have long physiological cycle half-life period, and have specific recognition to pathology organize, improved and increased medication effect of interferon to Hepatitis B, Hepatitis C etc. infectivity sickness and cancer, infect complication etc.
    Type: Grant
    Filed: December 27, 2002
    Date of Patent: May 4, 2010
    Assignee: Beijing Jiankai Technology Co., Ltd.
    Inventors: Shishan Ji, Dequan Zhu
  • Patent number: 7700551
    Abstract: The invention relates to Fmoc (9-fluorenyl-methoxycarbonyl)-based polymeric conjugates. These conjugates are useful for extending the in-vivo circulation of protein and peptide drugs.
    Type: Grant
    Filed: June 25, 2008
    Date of Patent: April 20, 2010
    Assignees: Baxter International Inc., Baxter Healthcare S.A.
    Inventors: Peter Turecek, Juergen Siekmann
  • Publication number: 20100086480
    Abstract: Methods for significantly lowering the carbon-14 content, particularly of DNA and histones in vertebrates, especially humans, to significantly below normal background levels and thereby reduce chromosomal damage using dietary supplements based on low radiocarbon DNA and histone precursors optionally including selected low radiocarbon amino acids, preferably including those which contribute the largest share of histone carbon atoms. Administration of the supplements during the earliest and/or most active growth stages of life is particularly beneficial. Components of the low radiocarbon supplements can be produced using a photobioreactor, an aqueous reaction medium and low radiocarbon carbon dioxide. The photobioreactor can be integrated into a body of water or can comprise a mobile, floating structure. Low radiocarbon by-products of photosynthesis can be recycled for use in non-photosynthetic fermentation processes to increase the yield of desirable supplement components.
    Type: Application
    Filed: November 3, 2009
    Publication date: April 8, 2010
    Applicant: RADIOCARB GENETICS, INC.
    Inventor: Christopher P. Williams
  • Patent number: 7682601
    Abstract: The present invention relates to a chelating agent of the general formula: (I), wherein m is 0 or 1; X is NR4 or S; Y is SR5, NHR5 or P(R5)2; R1 and R3 are the same or different and are selected from H, alkyl or aryl; R2 is H, COOH, NHR6 or (CH2)nCOOR6; R4 is H, alkyl, aryl, (CH2)nCOOR6 or (CH2)nOR6; R5 is H, alkyl, aryl, (CH2)nCOOR6 or (CH2)nOR6, R6 is H, alkyl or aryl; n is 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10; and when R1?R3?CH3, R2, R4 and R5 are not all three H. The invention further relates to a method and kit for the preparation of radiolabeled biomolecules while using the chelating agent.
    Type: Grant
    Filed: April 15, 2004
    Date of Patent: March 23, 2010
    Assignee: Mallinckrodt Inc.
    Inventors: Isabel Rego Santos, Joao Domingos Galamba Correia, Antonio Manuel Rocha Paulo, Susana Alves, Rute Vitor
  • Publication number: 20100040542
    Abstract: The present invention relates to improved chelator conjugates with biological targeting molecules, suitable for forming metal complexes with radiometals. The radiometal complexes, especially with the radiometal 99mTc, are useful as radiopharmaceuticals.
    Type: Application
    Filed: October 1, 2009
    Publication date: February 18, 2010
    Applicant: GE HEALTHCARE LIMITED
    Inventors: COLIN MILL ARCHER, HARRY JOHN WADSWORTH, TORGRIM ENGELL
  • Publication number: 20100015052
    Abstract: The invention relates to a method for improving stability of radiopharmaceutical precursors, and in particular non radiolabelled nucleoside derivatives which are used as precursors for production of radiolabelled nucleoside derivatives for use in in vivo imaging procedures such as positron emission tomography (PET). The invention further includes formulations of radiopharmaceutical precursors, and cassettes for automated synthesis apparatus comprising the same.
    Type: Application
    Filed: June 20, 2007
    Publication date: January 21, 2010
    Inventors: Svein Kvaale, Dirk-Jan In t Veld, Torild Wickstrom
  • Publication number: 20100008856
    Abstract: Radiolabeled tracers for sodium/glucose cotransporters (SGLTs), their synthesis, and their use are provided. The tracers are methyl or ethyl pyranosides having an equatorial hydroxyl group at carbon-2 and a C1 preferred conformation, radio-labeled with 18F, 123I, or 124I, or free hexoses radiolabeled with 18F, 123I, or 124I. Also provided are in vivo and in vitro techniques for using these and other tracers as analytical and diagnostic tools to study glucose transport, in health and disease, and to evaluate therapeutic interventions.
    Type: Application
    Filed: May 23, 2006
    Publication date: January 14, 2010
    Applicant: THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
    Inventors: Ernest M. Wright, Jorge R. Barrio, Bruce A. Hirayama, Vladimir Kepe
  • Publication number: 20100003189
    Abstract: Detection methods, assay kits and reagents are provided for detecting pre-cancerous mammary epithelial cell signatures. The disclosed cell signatures comprise a collection of measurements of at least two characteristics of the mammary epithelial cells. Related imaging and diagnostic methods are also disclosed.
    Type: Application
    Filed: July 3, 2007
    Publication date: January 7, 2010
    Applicant: THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
    Inventors: Thea D. Tlsty, Hal K. Berman, Mona L. Gauthier, Bob Y. Liu, Colleen A. Fordyce, Curtis R. Pickering, Paul A. Reynolds, Nancy Dumont, Geoffrey M. Benton
  • Publication number: 20090324497
    Abstract: Improved sst-receptor binding peptidic ligands for diagnostic and therapeutic applications in nuclear medicine are provided. The improved ligands contain either natural or unnatural amino acids or peptidomimetic structures that are modified at either the N-terminal or the C-terminal end or at both termini, a carbohydrate unit and a chelator or prosthetic group to provide a complexation of a radioisotope binding or holding the radioisotope. The sst- or SSTR-receptor binding peptidic ligands may also contain one or more multifunctional linker units optionally coupling the peptide, and/or the sugar moiety and/or the chelator and/or the prosthetic group. Upon administering the ligand to a mammal through the blood system the ligand provides improved availability, clearance kinetics, sst-receptor targeting and internalization over the non-carbohydrated ligands.
    Type: Application
    Filed: September 10, 2009
    Publication date: December 31, 2009
    Applicant: Mallinckrodt Inc.
    Inventors: Hans-Jurgen Wester, Margret Schottelius, Markus Schwaiger
  • Patent number: 7635463
    Abstract: This disclosure relates to compositions for delivering agents to a subject, and in particular, to compositions for delivery of therapeutic agents or diagnostic agents in the presence or absence of targeting moieties. In part, this disclosure relates to compositions comprising a hydrophobic group with a first end and a second end, a first metal binding domain linked to the hydrophobic group, a metal ion capable of being chelated to the first metal binding domain, and an agent linked to a second metal binding domain capable of chelating to the metal ion.
    Type: Grant
    Filed: June 21, 2007
    Date of Patent: December 22, 2009
    Assignee: Pharmain Corporation
    Inventors: Elijah M. Bolotin, Gerardo M. Castillo
  • Patent number: 7632484
    Abstract: The invention provides, in a general sense, a new labeling strategy employing 99mTc chelated with ethylenedicysteine (EC). EC is conjugated with a variety of ligands and chelated to 99mTc for use as an imaging agent for tissue-specific diseases. The drug conjugates of the invention may also be used as a prognostic tool or as a tool to deliver therapeutics to specific sites within a mammalian body. Kits for use in tissue-specific disease imaging are also provided.
    Type: Grant
    Filed: April 17, 2006
    Date of Patent: December 15, 2009
    Assignee: Board of Regents, The University of Texas System
    Inventors: David J. Yang, Chun W. Liu, Dong-Fang Yu, E. Edmund Kim
  • Publication number: 20090304587
    Abstract: The present invention discloses composites which generally comprise a polymeric matrix and a hydrophobic organic compound which is associated with a radioisotope.
    Type: Application
    Filed: November 1, 2006
    Publication date: December 10, 2009
    Applicants: Yissum Research Development Company Of The Hebrew University of Jerusalem, Hadasit Medical Research Services & Development Limited
    Inventors: Abraham Rubinstein, Abdel Kareem Azab, Boris Orkin, Aviram Nissan, Susan Haupt, Morris Srebnki, Raphael Udassin
  • Patent number: 7625872
    Abstract: The invention provides immunomodulatory compounds and methods for immunomodulation of cells and individuals using the immunomodulatory compounds.
    Type: Grant
    Filed: December 17, 2003
    Date of Patent: December 1, 2009
    Assignee: Dynavax Technologies Corporation
    Inventor: Karen L. Fearon